SCHEMBL298096

SCHEMBL298096

O=C(c1c(F)ccc(NS(=O)(=O)C2CCC2)c1F)c1c[nH]c2ncc(Cl)cc12

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C19 P33261 9/20 0.68
BRAF P15056 7/20 0.68
CYP2C9 P11712 6/20 0.68
RIPK2 O43353 2/20 0.68
RAF1 P04049 2/20 0.68
KDR P35968 2/20 0.68
MAP2K2 P36507 2/20 0.68
TGFBR2 P37173 2/20 0.68
NEK2 P51955 2/20 0.68
MAP2K1 Q02750 2/20 0.68
TNK2 Q07912 2/20 0.68
MAP2K5 Q13163 2/20 0.68
PTK6 Q13882 2/20 0.68
NEK11 Q8NG66 2/20 0.68
MAP3K20 Q9NYL2 2/20 0.68
MAP4K5 Q9Y4K4 2/20 0.68
BMPR1B O00238 1/20 0.68
PLK4 O00444 1/20 0.68
PIR O00625 1/20 0.68
AURKA O14965 1/20 0.68

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL299581 0.98 CYP2C19 (0.68) CYP2C19BRAFCYP2C9RIPK2RAF1
SCHEMBL297865 0.97 CYP2C19 (0.67) CYP2C19BRAFCYP2C9RIPK2RAF1
SCHEMBL20408852 0.91 BRAF (0.70) CYP2C19BRAFCYP2C9RIPK2RAF1
SCHEMBL298758 0.90 CYP2C19 (0.68) CYP2C19BRAFCYP2C9RIPK2RAF1
SCHEMBL20399270 0.89 BRAF (0.70) CYP2C19BRAFCYP2C9RIPK2RAF1
SCHEMBL299293 0.88 CYP2C19 (0.68) CYP2C19BRAFCYP2C9RIPK2RAF1
SCHEMBL20399219 0.88 BRAF (0.69) CYP2C19BRAFCYP2C9RIPK2RAF1
SCHEMBL298925 0.88 CYP3A4 (0.67) CYP2C19BRAFCYP2C9RIPK2RAF1
SCHEMBL10245866 0.88 CYP2C19 (0.53) CYP2C19BRAFCYP2C9RIPK2RAF1
SCHEMBL299112 0.88 CYP2C19 (0.67) CYP2C19BRAFCYP2C9RIPK2RAF1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120122860-A1 SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS PLEXXIKON, INC. 2012-05-17 US disclosed
US-20120122860-A1 SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS PLEXXIKON, INC. 2012-05-17 US disclosed
EP-2427433-A1 SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS Plexxikon, Inc. (US) 2012-03-14 EP disclosed
WO-2010129570-A1 SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS PLEXXIKON, INC. (US) 2010-11-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120122860-A1 SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS BRAF, RAF1, ARAF CYP2C19 2730/4885BRAF 1/4885CYP2C9 2176/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.